

# Journal of Digital Imaging

## Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence --Manuscript Draft--

<b>Manuscript Number:</b>	JDIM-D-17-00030R1	
<b>Full Title:</b>	Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence	
<b>Article Type:</b>	Original Paper	
<b>Funding Information:</b>	National Cancer Institute (1U01CA160045)	Dr. Bradley J Erickson
<b>Abstract:</b>	<p>Several studies have associated codeletion of chromosome arms 1p/19q in low-grade gliomas (LGG) with positive response to treatment and longer progression free survival. Hence, predicting 1p/19q status is crucial for effective treatment planning of LGG. In this study, we predict the 1p/19q status from MR images using convolutional neural networks (CNN), which could be a noninvasive alternative to surgical biopsy and histopathological analysis. Our method consists of three main steps: image registration, tumor segmentation, and classification of 1p/19q status using CNN. We included a total of 159 LGG with 3 image slices each who had biopsy-proven 1p/19q status (57 nondeleted and 102 codeleted) and preoperative postcontrast-T1 (T1C) and T2 images. We divided our data into training, validation, and test sets. The training data was balanced for equal class probability and then augmented with iterations of random translational shift, rotation, and horizontal and vertical flips to increase the size of the training set. We shuffled and augmented the training data to counter overfitting in each epoch. Finally, we evaluated several configurations of a multi-scale CNN architecture until training and validation accuracies became consistent. The results of the best performing configuration on the unseen test set were 93.3% (sensitivity), 82.22% (specificity), and 87.7% (accuracy). Multi-scale CNN with their self-learning capability provides promising results for predicting 1p/19q status noninvasively based on T1C and T2 images. Predicting 1p/19q status noninvasively from MR images would allow selecting effective treatment strategies for LGG patients without the need for surgical biopsy.</p>	
<b>Corresponding Author:</b>	Bradley Erickson, M.D. Ph.D. Mayo Clinic - Rochester Rochester, Minnesota UNITED STATES	
<b>Corresponding Author Secondary Information:</b>		
<b>Corresponding Author's Institution:</b>	Mayo Clinic - Rochester	
<b>Corresponding Author's Secondary Institution:</b>		
<b>First Author:</b>	Zeynettin Akkus	
<b>First Author Secondary Information:</b>		
<b>Order of Authors:</b>	Zeynettin Akkus Issa Ali, BSc Jiri Sedlar, PhD Jay P Agrawal, MD Ian F Parney, MD, PhD Caterina Giannini, MD, PhD Bradley J Erickson, MD, PhD	
<b>Order of Authors Secondary Information:</b>		
<b>Author Comments:</b>	Dear Editor,	

This manuscript is revised submission for the special focus issue of C-MIMI conference in Alexandria in September 2016.

We have answered reviewers' comments and made changes in the revised manuscript based on their comments. All changes were highlighted with yellow background.

We also changed the authorship listed in the computer system to match the list on the title page. The title page is correct, but the form was not.

Please feel free to contact me if you have any questions.

Sincerely,  
Zeynettin Akkus, PhD

[Click here to view linked References](#)

# Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence

## ABSTRACT

Several studies have associated codeletion of chromosome arms 1p/19q in low-grade gliomas (LGG) with positive response to treatment and longer progression free survival. Hence, predicting 1p/19q status is crucial for effective treatment planning of LGG. In this study, we predict the 1p/19q status from MR images using convolutional neural networks (CNN), which could be a noninvasive alternative to surgical biopsy and histopathological analysis. Our method consists of three main steps: image registration, tumor segmentation, and classification of 1p/19q status using CNN. We included a total of 159 LGG with 3 image slices each who had biopsy-proven 1p/19q status (57 nondeleted and 102 codeleted) and preoperative postcontrast-T1 (T1C) and T2 images. We divided our data into training, validation, and test sets. The training data was balanced for equal class probability and then augmented with iterations of random translational shift, rotation, and horizontal and vertical flips to increase the size of the training set. We shuffled and augmented the training data to counter overfitting in each epoch. Finally, we evaluated several configurations of a multi-scale CNN architecture until training and validation accuracies became consistent. The results of the best performing configuration on the unseen test set were 93.3% (sensitivity), 82.22% (specificity), and 87.7% (accuracy). Multi-scale CNN with their self-learning capability provides promising results for predicting 1p/19q status noninvasively based on T1C and T2 images. Predicting 1p/19q status noninvasively from MR images would allow selecting effective treatment strategies for LGG patients without the need for surgical biopsy.

*Keywords*— Low grade gliomas, 1p/19q codeletion, therapy response, convolutional neural networks

## I. INTRODUCTION

Magnetic resonance (MR) imaging is a non-invasive medical imaging technique that provides outstanding soft tissue contrast and has become the standard imaging technique for brain tumor diagnosis [1]. Gliomas are the most frequent primary brain tumors originating in the brain [2]. World Health Organization (WHO) classifies them into four grades based on their aggressiveness. Low-grade gliomas (LGG), also named diffuse low-grade and intermediate-grade gliomas (WHO grades II and III), include oligodendrogliomas, astrocytomas, and oligoastrocytomas [3-5]. Compared to high-grade gliomas (HGG: WHO grade IV, glioblastoma), LGG are less aggressive tumors with better prognosis. A subgroup of LGG will progress to glioblastoma (HGG, grade IV), but other subgroups will progress slower or remain stable [4, 6-8]. In addition, some LGG are sensitive to therapy and their survival ranges from 1 to 15 years [8, 6]. Presently, treatment includes observation, surgery, radiotherapy, and chemotherapy either separately or in combination [4]. Although histological grading of tumors is the gold standard for diagnosis and subsequent treatment planning, it is known that histopathological diagnosis lacks information about other tumor properties (e.g. genomic biomarkers) that can impact optimal therapy options [3]. Therefore, other tests of LGG (e.g. molecular biomarkers testing) are also obtained to improve treatment planning. Several studies [9-12] have shown that codeletion of 1p/19q chromosome arms is a strong prognostic molecular marker for positive tumor response to chemotherapy and radiotherapy in LGG and associated with longer survival. Therefore, predicting 1p/19q status is crucial for effective treatment planning of LGG.

Currently, determining 1p/19q status requires surgical biopsy typically followed by fluorescence in-situ hybridization (FISH) [13] to identify chromosomal deletion. Several studies have shown that imaging can predict 1p/19q status from MR images or positron emission tomography (PET) images. Fellah et al. [9] presented univariate analysis and multivariate random forest models to determine 1p/19q status from multimodal MR images including conventional MR images, diffusion weighted imaging (DWI), perfusion weighted imaging (PWI), and MR spectroscopy. DWI, PWI, and MRI spectroscopy showed no significant difference between tumors with and without 1p/19q loss in their study. They concluded that inclusion of DWI, PWI, and MR spectroscopy was not useful for determining 1p/19q status compared with conventional MR images. Jansen et al. [10] presented detection of 1p/19q status from [ $^{18}\text{F}$ ] fluoroethyltyrosine-PET (FET-PET) images. They derived several biomarkers from PET images and correlated with 1p/19q status, and showed that these biomarkers do not reliably predict the status of 1p/19q in individual patients. Iwadata et al. [11] studied detection of 1p/19q codeletion from  $^{11}\text{C}$ -methionine PET images and concluded that  $^{11}\text{C}$ -methionine PET might help discriminate tumors with and without 1p/19q codeletion preoperatively. Bourdillion et al. [12] presented prediction of anaplastic transformation in grade 2 oligodendrogliomas based on MR spectroscopy and 1p/19q status. They showed that choline/creatine ratio  $>2.4$  was associated with the occurrence of anaplastic transformation in patients without 1p/19q codeletion. On the other hand, no anaplastic transformation was observed in patients with 1p/19q codeletion.

In this study, we present a robust, and noninvasive method to predict the 1p/19q status of LGG from post-contrast T1 and T2 weighted MR images using convolutional neural networks (CNN).

## II. MATERIAL AND METHODS

We use a combination of two commonly acquired image types, T2 and post-contrast T1 weighted images, as input to our classification algorithm. Figure 1 shows examples of LGG image characteristics in post-contrast T1 and T2 weighted images with and without 1p/19q codeletion. Our classification algorithm consists of several pre-processing steps: Multi-modal image registration, tumor segmentation, data normalization, and data augmentation. After applying pre-processing steps to data, we use the segmented images to train a multi-scale CNN for prediction of 1p/19q status. A flowchart and implementation details of the multi-scale CNN are shown in Figure 2.

### A. Brain Tumor Data

One hundred fifty nine ( $n=159$ ) consecutive (01-Oct-2002 – 01-Aug-2011) pre-operative LGG patients, with stereotactic MRI images, who had biopsy proven 1p/19q status consisting either no deletion or co-deletion, were identified from our brain tumor patient database at Mayo Clinic for this study. The data included 102 nondeleted and 57 codeleted LGG. The types of LGG were oligoastrocytoma ( $n = 97$ ), oligodendrogliomas ( $n = 45$ ), and astrocytomas ( $n = 17$ ). In total, 477 slices (3 slices per LGG including one centered at the tumor ‘equator’ plus one slice above and below) were included for this study. Post-contrast T1 and T2 weighted images were available for all selected patients. Institutional Review Board (IRB) approval was obtained for this study and requirement for patient consent was waived.

All images were acquired for biopsy planning purposes, and so a very consistent scanning protocol was used, including 3mm thick T2 images and 1mm thick axial spoiled-gradient recalled images all acquired at 1.5T or 3T on either General Electric Medical System (Waukegan, WI) or Siemens Medical System (Malvern, PA) scanner.




Figure 1: An example of low-grade glioma with and without 1p/19q codeletion. Images a and b show T2 and post contrast T1 for nondeleted 1p/19q. Images c and d show T2 and post contrast T1 for codeleted 1p/19q.

### B. Pre-processing

#### Multi-modal Image Registration

We registered post-contrast T1 weighted images to T2 weighted images of the same patient by using the ANTs open source software library for image registration [14, 15]. We performed rigid registration using cubic b-spline interpolation and mutual information metric, which takes into account translational movements, to align our intra-patient images.

#### Tumor Segmentation

We used our semi-automatic LGG segmentation software to segment the tumors in 2D [16]. First, the user selects the slice where the area of the tumor appears largest, and then draws a region-of-interest (ROI) that completely encloses the tumor and some normal tissue. Second, a normal brain atlas [17] and post-contrast T1 weighted images are registered to T2 weighted images. Third, the posterior probability of each pixel/voxel belonging to normal and abnormal tissues is calculated based on information derived from the atlas and ROI. Finally, geodesic active contours [18] use the probability map of the tumor to shrink the ROI until optimal tumor boundaries are found. With that, a morphological binary dilation of five pixels is applied to make sure boundaries are included in the tumor ROI.

#### Data Normalization

After registration and segmentation steps, the dataset of raw MR image data is normalized to balance intensity values and narrow the region of interest. This step aims to finely tune the input information fed into the CNN. The normalization process begins with skull-stripping using Brain Extraction Tool (BET) [19] based on FSL library [20], then followed by standard scoring. Standard scores (also called z-scores) are calculated for each image by subtracting the mean of image intensities from an individual intensities and then dividing the difference by the standard deviation of the image intensities (see Eq. 1).

$$z = \frac{X - \mu}{\sigma}$$

Eq.1

where  $X$  is image intensities,  $\mu$  is mean of the image intensities, and  $\sigma$  is the standard deviation of the image intensities.




Figure 2: A flowchart of the multi-scale CNN architecture. Blue box is the input image. Yellow boxes are convolutional layers. Green boxes are rectified linear units (RELU), activations. Red Boxes are max pooling layers. Purple boxes are fully connected layers plus a softmax binary classifier. Cyan circle shows the output label.

### Data Augmentation

Using deep networks, in particular CNNs, there is a high susceptibility to overfitting. This is a direct result of the large number of network parameters relative to the number of features provided by the MR images. The number of features available from MR images may not be sufficient to provide sufficient learning and generalizability to the parameters in the network, hence the need to increase the number of MR images. One approach to address this is through artificially augmenting the dataset using label-preserving transformations [21]. This “data augmentation” consists of generating image translations, rotations, and horizontal and vertical flipping. We apply a random combination of these transformations on each image, hence creating “new” images. This multiplies our dataset by several fold and help reduce over-fitting.

### C. Convolutional Neural Networks

Convolutional Neural Networks (CNN) is a type of feed-forward artificial neural network for learning a hierarchical representation of image data [22]. Unlike a regular Neural Network, the layers of a CNN have neurons arranged in 3 dimensions (width, height, and depth) and respond to a small region of the input image, called receptive field, instead of all of the neurons in a fully-connected manner. Each neuron learns to detect features from a local region the input image. This allows capturing features of local structures and preserving the topology of the input image. The final output layer will reduce the full image into a single vector of class scores, arranged along the depth dimension.

The main types of layers needed to build a CNN deep learning system are: input layer, convolutional layer, activation layer, pooling layer, and fully connected layer. Most implementations have many of each type of layer, hence the title ‘deep’ learning. Each layer is described in more detail.

**Input layer:** This layer holds the raw pixels values of the input image after applied pre-processing steps.

**Convolutional layer:** This layer is composed of several feature maps along the depth dimension, each corresponding to a different convolution filter. All neurons with the same spatial dimension (width and height) are connected to the same receptive field in the input image or, generally, in the previous layer. This allows capturing a wide variety of imaging features. The depth of the layer, i.e. the number of convolution filters, defines the number of features that can be extracted from each input receptive field. Each neuron in a feature map shares exactly the same weights, which define the convolution filter. This allows reducing the number of weights, and thus increasing the generalization ability of the architecture.

**Activation layer:** This layer applies an activation function to each neuron in the output of the previous layer. For example, rectified linear unit (RELU) where  $\text{RELU}(x) = \max(0, x)$  is the most common activation function used in CNNs architectures and fires the real value of the output and thresholds at zero. This layer does not change the size of the previous layer. It simply replaces negative values with ‘0’.

**Pooling layer:** Placed after an activation layer and this layer down-samples along spatial dimensions (width and height). It selects the invariant imaging features by reducing the spatial dimension of the convolution layer. The most popular type is max pooling, which selects the maximum value of its inputs as the output, thus preserving the most prominent filter responses.

Fully connected layer: As with neural networks, this layer connects all neurons in the previous layer to this layer with a weight for each such connection. If used as the output, each output nodes represents the ‘score’ for each possible class.

To allow learning of complex relationships and to achieve a more hierarchical representation of the input image, multiple convolutional-pooling layers are stacked to form a deep architecture of multiple nonlinear transformations. This allows learning a hierarchy of complex features carrying predictive power for image classification tasks.

### *Multi-Scale CNN parameters*

In our study, we use a CNN architecture that consists of different sizes of convolutional filters to train on our dataset (see Figure 2). This can be considered as multi-scale CNN that learns global and local imaging features with different convolutional filter sizes and concatenates their output before the classification step. The parameters of each layer are seen in the boxes in Figure 2. For example, the size of the first convolutional layer in the first branch is 128x200x200 and corresponds to depth of layer, 128 filters, and size of filters 200 by 200 in 2D spatial space ( $x, y$ ). Default stride size is 1 pixel in  $x$  and  $y$ . Specific strides for each layer are shown in the boxes. Since every tumor has a different shape and size, we embedded each 2D tumor slice into standard background (zero intensity level) of size 205 by 205 pixels, which is the smallest that encompasses the largest tumor size in our data set.

In our architecture, probability of tumor slices belonging to each class were computed with softmax classifier and the parameters of the CNN were updated by minimizing a negative log likelihood loss function [23]. We used a stochastic gradient descend (SGD) [24] algorithm with mini batches of 32 samples in our study. The SGD algorithm with mini batches is commonly used to train neural networks on large datasets because it efficiently finds good values without high computation or memory requirements. Specifically, only a small batch of training data at a time is used at each update of weights instead of using all training samples to compute the gradient of the loss function. The learning rate was initially set to 0.001 and decreased 50% at every 50 epoch. The training was stopped when the change in validation loss smaller 0.02 for 10 consecutive epochs.

## III. IMPLEMENTATION AND EXPERIMENTS

### *Implementation*

Our code is based on the Keras package [25], built on top of Theano library, a Python library. Keras can leverage Graphical Processing Units (GPUs) to accelerate the deep learning algorithms. We trained our CNN architecture on an NVIDIA GTX 970 GPU card. The training took about 10 minutes to 2 days depending on the amount of the used data. For example, using 30-fold augmented data as the training data at each epoch took about 2 days to train the network.

### *Experiments*

We divided our data ( $n=477$  slices) into training and test sets. A total of 90 slices (45 nondeleted and 45 codeleted) were randomly selected from the data at the beginning, as a test set, and never seen by the CNN during the training. From the remaining data ( $n=387$ ), 252 slices that were balanced for equal class probability ( $n = 126$  codeleted + 126 nondeleted) were randomly selected at each epoch for training. Twenty percent of the training set was separated as validation set ( $n = 68$ ) during the training. The data augmentation was applied to the training set ( $n = 7560$  for 30-fold augmentation) at each epoch to increase the training samples and achieve generalization ability.

We used the performance of our CNN architecture on validation set to tune the hyper-parameters of the CNN. Since our architecture includes multi-size of convolutional filters and multi-branch CNN, it takes into account a range of values for hyperparameters in the architecture. For further tuning of hyperparameters, we first investigated the contribution of each image channel for prediction of 1p/19q status. Therefore we experimented three configurations of our multi-scale CNN based on combinations of input images without data augmentation, i.e. T1 only (Configuration 1), T2 only (Configuration 2), and T1 and T2 combined (Configuration 3). We selected the best configuration (Configuration 3) among these based on their performance on the test set. Next, we trained the best configuration from above with multiple folds  $k \in \{10, 20, 30\}$  of data augmentation to tune the  $k$  hyper-parameter of the data augmentation. To evaluate the influence of different optimizers on learning, we compared the performances of our CNN architecture using four different optimizers: SGD, root mean square propagation (RMSprop), improved adaptive gradient algorithm (AdaDelta), and adaptive moment estimation (Adam). Configuration 4 was defined as the one using the best performing parameters and data augmentation. For each configuration, sensitivity, specificity, and accuracy were computed as follows:

Sensitivity or True Positive Rate ( $TPR$ ):

$$TPR = \frac{TP}{TP + FN}$$

where TP is true positives, FN is false negatives



Specificity ( $SPC$ ) or True Negative Rate:

$$SPC = \frac{TN}{TN + FP}$$

where  $TN$  is true negatives,  $FP$  is false positives

and accuracy ( $ACC$ ):

$$ACC = \frac{TP + TN}{TP + FP + TN + FN}$$

We also compared the performance of our method to the performance of a classical machine-learning algorithm using support vector machine (SVM) classifier with greedy feature selection. Using seven selected features (from intensity-based features, local binary patterns, Gabor filters, Laplacian of Gaussian, gray-level co-occurrence matrix, and boundary sharpness) the SVM classifier was trained and tested on the same data.

#### IV. RESULTS

Figure 3 shows that the multi-scale CNN is overfitting to the original (limited size) training data, when data augmentation is not used, as the distance between the training and validation losses increases over time. The accuracy approaches 100% after 50 epochs for the training set and the loss gets closer to zero, but the performance of trained CNN without data augmentation remains below 80% for the test data (see Table 1). As seen in the Table 1, the performance of CNN with data augmentation (Configuration 4) is better than the other configurations without data augmentation.



Figure 3: Loss plots are shown for the training and validation sets on the original data for configuration 4.




Figure 4: Accuracy (left) and loss (right) plots are shown for the training of the best performing configuration (4) on the augmented data.

Data augmentation of original data with  $k=30$ -fold ( $ACC = 89.5$ ) gave the better accuracy on the validation dataset compared to the ones using  $k=10$ -fold ( $ACC = 85.5$ ) and  $k=20$ -fold ( $ACC = 83.3$ ) augmentations. Compared to training on the data without augmentation, accuracy and loss in Figure 5 fluctuate and are noisier due to variations introduced with data



augmentation. The results of the SVM classifier using texture features on the test set were 80% (sensitivity), 82% (specificity), and 81% (accuracy), which are inferior than the results of multi-scale CNN (configuration 4).

Table 2 compares the performance of the best performing configuration using 4 different optimizers. As seen in Table 2, the influence of optimizers on learning is not much and SGD gives better performance on the test data compared to other optimizers. Figure 4 shows the performance of the best performing CNN configuration 4 on the training data. Fluctuations seen in Figure 4 are due to randomly introduced augmented data at each epoch. Table 1 shows the performance of multi-scale CNN configurations on the test dataset. Figure 5 shows the validation loss of the best performing CNN (configuration 4) on the validation set. As seen in figure 4 and 5 the training and validation losses converge to same value of about 0.2 over time. Table 3 shows the confusion matrix of 1p19q status on test set for the best performing CNN (configuration 4). False negatives are higher than false positives.




Figure 5: Validation loss is shown on the validation set for the best performing configuration (configuration 4) using data augmentation.

Table 1: Statistics for Test Set			
Configurations	Sensitivity	Specificity	Accuracy
1	80.0%	46.7%	63.3%
2	86.7%	64.4%	75.6%
3	84.4%	73.3%	78.9%
4	93.3%	82.2%	87.7%

Table 1: Table shows sensitivity, specificity, and accuracy for each configuration of multi-scale CNN for the test set. Configurations: 1- using T1C only and no augmentation (NA), 2-using T2 only and NA, 3: using T1C and T2 combined (T1T2) and NA, 4-using T1T2 and 30-fold AG and further training.

Table 2: Statistics for Optimizers			
Configurations	Sensitivity	Specificity	Accuracy
SGD	93.3%	82.2%	87.7%
RMSprop	84.4%	84.4%	84.4%
AdaDelta	82.2%	84.4%	83.3%
Adam	88.8%	82.2%	85.5%

Table 2: The performance of the best CNN configuration using four different optimizers on the test dataset was shown.

n=90		Predicted Labels	
		Co-deleted	Non-deleted
Actual Labels	Co-deleted	42	3
	Non-deleted	8	37

Table 3: Confusion matrix of classification of 1p19q status on test set for the best CNN (configuration 4).

## V. DISCUSSION

In this study, we present a robust and noninvasive method to predict 1p/19q chromosomal arms deletion from post-contrast T1 and T2 weighted MR images using multi-scale CNN approach. As mentioned in previous studies [4, 6-8], a subset of LGG are sensitive to therapy and have longer progress free survival while others may progress to HGG. Although histologic grade is the most important factor in therapeutic decision-making, it lacks information about other tumor properties that can impact optimal therapy options and recent reports suggest genomic marker may be more predictive than histologic grade [26]. Adding other information such as 1p/19 chromosomal arms deletion, which has been associated with positive response to therapy, could help improve therapeutic decision-making.

An important challenge in applying deep learning methods to medical images is having an adequate number of data sets. Our multi-scale CNN reached to 100% sensitivity, specificity, and accuracy in training set without data augmentation (see Figure 3), but had less than 80% specificity and accuracy for the (unseen) test set (see Table 1). This demonstrated that our algorithm did not truly learn the distinctive imaging features, but rather, overfit to the training examples. As seen in Table 1, configuration 4 using augmented data to train our multi-scale CNN approach perform better than the other configurations on the unseen test dataset. Fluctuations as seen in Figure 4 are results of introducing new augmented training data at each epoch. As seen in the results, augmenting a randomly selected set of the original training data, which is described in the experiment section, at each epoch improves generalization ability of the multi-scale CNN and prevents overfitting. As seen in Table 1, configuration 4 yields the best performance on the test dataset. The performance of configuration 4 in the training and validation datasets is in the same order with its performance in the test dataset. This highlights the generalizability of configuration 4 and its minimal overfitting.

The misclassification rate on the test dataset is about 11%. Some part of this error might be due to the error rate introduced by the FISH test that was used to determine the 1p/19 status. Scheie et al. [13] showed that the reliability of FISH test was 95% and 87.5% for the detection of 1p and 19q deletions, respectively.

As seen in Figure 5, the loss on validation dataset for configuration 4 stops fluctuating and stabilizes with slight changes after 400 epochs for several epochs. This means that the network not learning much any more and had converged to a steady state. As seen Table 2, SGD optimizer gave superior performance on the test dataset compared to other three optimizers.

As seen in our results deep learning algorithm performs better than the classical machine-learning algorithm using SVM. As mentioned before, Fellah et al. [9] presented the first study that determined the 1p/19q status from DWI, PWI, MR spectroscopy and conventional MR images. Their misclassification rates were 48% and 40% for using only the conventional MR images and using all multimodal images, respectively. Compared to their results, our best-performing configuration (4) show better performance in our dataset, with 93.3% sensitivity, 82.2% specificity, and 87.7% accuracy in the unseen test dataset. Moreover, our data was evaluated in a larger dataset (159 LGG vs. 50 LGG). However, it is hard to make the direct comparison since we used different datasets. To the best of our knowledge, our study is the first using the deep learning to predict 1p19q from MR images in LGGs.

Although the original data size was limited, artificially augmenting data helped increase the volume of our data. It may be that further performance gains will be realized with larger patient populations with more heterogeneous data. Furthermore, including weight regularization such as L1 or L2 in the network might improve generalizability of our networks. Further studies with larger patient populations are required to investigate these and confirm our current findings.

## VI. CONCLUSIONS

Our multi-scale CNN approach provides promising results for predicting 1p/19q codeletion status noninvasively, based on post-contrast T1 and T2 images. **Data augmentation helps counter overfitting and provides learning the invariant patterns in the images.** Our presented method could be further improved and potentially used as an alternative to surgical biopsy and pathological analysis for predicting 1p/19q codeletion status.

### ACKNOWLEDGEMENTS:

This work was supported by National Institutes of Health 1U01CA160045.

### CONFLICT OF INTEREST:

The authors declare that there is no conflict of interest.

## REFERENCES:

1. DeAngelis LM. Brain tumors. *N Engl J Med*. 2001;344(2):114-23. doi:10.1056/nejm200101113440207.
2. Cha S. Update on brain tumor imaging: from anatomy to physiology. *AJNR Am J Neuroradiol*. 2006;27(3):475-87.
3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. *Brain Pathol*. 1993;3(3):255-68.
4. Network TCGAR. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*. 2015;372(26):2481-98.
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO Classification of Tumours of the Central Nervous System. *Acta Neuropathologica*. 2007;114(2):97-109.
6. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(3):344-50.
7. van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. *Neuro Oncol*. 2014;16(12):1570-4. doi:10.1093/neuonc/nou297.
8. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. *Annals of neurology*. 1990;27(5):573-4.
9. Fella S, Caudal D, De Paula AM, Dory-Lautrec P, Figarella-Branger D, Chinot O et al. Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis? *Am J Neuroradiol*. 2013;34(7):1326-33.
10. Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas. *Neuro-Oncology*. 2012;14(12):1473-80.
11. Iwade Y, Shinozaki N, Matsutani T, Uchino Y, Saeki N. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016.
12. Bourdillon P, Hlaïhel C, Guyotat J, Guillotton L, Honnorat J, Ducray F et al. Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. *J Neuro-Oncol*. 2015;122(3):529-37.
13. Scheie D, Andresen PA, Cvancarova M, Bo AS, Helseth E, Skullerud K et al. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. *The American journal of surgical pathology*. 2006;30(7):828-37.
14. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage*. 2011;54(3):2033-44.
15. Avants BB, Tustison NJ, Stauffer M, Song G, Wu B, Gee JC. The Insight ToolKit image registration framework. *Front Neuroinform*. 2014;8:44.
16. Akkus Z, Sedlar J, Coufalova L, Korfiatis P, Kline TL, Warner JD et al. Semi-automated segmentation of pre-operative low grade gliomas in magnetic resonance imaging. *Cancer Imaging*. 2015;15:12.
17. Rohlfing T, Zahr NM, Sullivan EV, Pfefferbaum A. The SRI24 Multi-Channel Atlas of Normal Adult Human Brain Structure. *Human brain mapping*. 2010;31(5):798-819.
18. Marquez-Neila P, Baumela L, Alvarez L. A morphological approach to curvature-based evolution of curves and surfaces. *IEEE Trans Pattern Anal Mach Intell*. 2014;36(1):2-17. doi:10.1109/tpami.2013.106.
19. Smith SM. Fast robust automated brain extraction. *Human Brain Mapping*. 2002;17(3):143-55. doi:10.1002/hbm.10062.
20. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. *Fsl. Neuroimage*. 2012;62(2):782-90.
21. Krizhevsky A, Ilya Sutskever, and Geoffrey E. Hinton. Imagenet classification with deep convolutional neural networks. *Advances in Neural Information Processing Systems*. 2012.
22. Lecun Y, Bottou L, Bengio Y, Haffner P. Gradient-based learning applied to document recognition. *Proceedings of the IEEE*. 1998;86(11):2278-324.
23. Ypsilantis P-P, Siddique M, Sohn H-M, Davies A, Cook G, Goh V et al. Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. *PLoS ONE*. 2015;10(9)
24. Tsuruoka Y, Tsujii Ji, Ananiadou S. Stochastic gradient descent training for L1-regularized log-linear models with cumulative penalty. *Proceedings of the Joint Conference of the 47th Annual Meeting of the ACL and the 4th International Joint Conference on Natural Language Processing of the AFNLP Association for Computational Linguistics*; 2009. p. 477-85.
25. Chollet F. Keras. Github (<https://github.com/fchollet/keras>). 2015.
26. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *New England Journal of Medicine*. 2015;372(26):2499-508.




Figure2

[Click here to download Figure Figure2.jpg](#)









Figure4

[Click here to download Figure Figure4.jpg](#)







Comments to the author (if any):

Reviewer #1: Dear Authors,

You studied on MRI images with Deep Learning (CNN)

Why do you create Table 1, Training on Original Data, Training Loss on Original Data, Training Accuracy on Augmented Data and Training Loss on Augmented Data ? Training results are actually useless at the research

You use different optimizers that are not explained how to work (Table 4). Why SGD configuration is better than others, you need to explain. Also, Other tables are needed that what these results mean.

Tables and Figures are not explained good enough to understand what it shows.

Conclusion doesnot give enough information about the manuscript.

*Answer: We agree with the reviewer training results are redundant. We removed the tables and figures that are not informative. Instead, we put one figure (Figure 3) that shows the overfitting. We also further explained the results (Modified, Page 6,7).*

*To evaluate the influence of optimizer on learning, we compared the performances of our CNN architecture using four different optimizers. (Added to Page 5)*

*"Table 2 compares the performance of the best performing configuration using 4 different optimizers. As seen in Table 2, the influence of optimizers on learning is not much and SGD gives better performance on the test data compared to other optimizers." (Modified, Page 7)*

*We also added this to conclusion: "Data augmentation helps counter overfitting and provides learning the invariant patterns in the images" (Added, Page 8)*

Reviewer #2: The paper "Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence" aims to predict the status of 1p/19q based on the information encoded in MR images using to do so CNN classifier.

In Page 2, Lines 12-14: "... it is known that histopathological diagnosis lacks information about other tumor properties that can impact optimal therapy options..." Two problems here. a) Which other properties and; b) "...it is known..." requires a reference.

*Answer: We agree with the reviewer that this was not clear and we modified the sentence and added a reference. Although histological grading of tumors is the gold standard for diagnosis and subsequent treatment planning, it is known that histopathological diagnosis lacks information about other tumor properties (e.g. genomic biomarkers) that can impact optimal therapy options [3].*

Regarding the classifier. In Subsection C (pg 4, lines 39-44) you describe the characteristics of CNN. Those are probably the reason why you favored CNN instead of other types of classifiers. It would be beneficial if you made this fact explicit in your text. Something like: "...given such characteristics this is the main reason why we opt to use CNN as classifier..." A reader knowledgeable about machine learning will got to ask: Why this classifier?

*Answer: As stated in page 6,, we compared the CNN to support vector machine classifier using texture features. "We also compared the performance of our method to the performance of a classical machine-learning algorithm using support vector machine (SVM) classifier with greedy feature selection. Using seven selected features (from intensity-based features, local binary patterns, Gabor filters, Laplacian of Gaussian, gray-level co-occurrence matrix, and boundary sharpness) the SVM classifier was trained and tested on the same data." (Page 6). "The results of the SVM classifier using texture features on the test set were 80% (sensitivity), 82% (specificity), and 81% (accuracy), which are inferior than the results of multi-scale CNN (configuration 4)." (Page 7)*

There is also a strong correlation between CNN and deep learning. Maybe you could consider to exploit it in order to improve the validity of the selected method? This do not hinder the value in any way. Just could help. Feel free do ignore such observation.

The experiments were well designed and the results are satisfactory.

I just got to wonder if any other classifier was considered and in doing so, it the results would be better or worst.

From my point of view, the data gathering and data preparation (registration, segmentation, ...) encompass a large portion of the work done, and the classifier is just one among all the necessary steps. I have to argue why not try at least another

classifier in order to ensure you really selected the most adequate to the problem at hand.

***Answer:*** As stated in the previous answer, we compared to another classifier and the results of SVM were inferior than the results of CNN.



### Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

[springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/before-you-start](http://springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/before-you-start)

All authors of papers submitted to Journal of Digital Imaging  
(name of journal) must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s). Please note that you cannot save the form once completed. Kindly print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).



I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using

Manuscript No. (if you know it) JDIM-D-17-00030

Author name Zeynettin Akkus

Are you the corresponding author? ☒ Yes ☐ No

Herewith I confirm that the information provided is accurate.

Author signature  Date 03/07/2017

# Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence

<sup>1</sup>\*Zeynettin Akkus, PhD; <sup>1</sup>Issa Ali, BSc; <sup>1</sup>Jiří Sedlář, PhD; <sup>1</sup>Jay P. Agrawal, MD; <sup>3</sup>Ian F. Parney, MD, PhD; <sup>2</sup>Caterina Giannini, MD, PhD; <sup>1</sup>Bradley J. Erickson, MD, PhD

<sup>1</sup>Radiology Informatics Lab, Mayo Clinic, Rochester, MN, USA

<sup>2</sup>Department of Pathology, Mayo Clinic, Rochester, MN, USA

<sup>3</sup>Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA)

\*Corresponding Author: Bradley J. Erickson

200 First Street SW

Rochester, MN 55905

[bje@mayo.edu](mailto:bje@mayo.edu)

## ABSTRACT

Several studies have linked codeletion of chromosome arms 1p/19q in low-grade gliomas (LGG) with positive response to treatment and longer progression free survival. Hence, predicting 1p/19q status is crucial for effective treatment planning of LGG. In this study, we predict the 1p/19q status from MR images using convolutional neural networks (CNN), which could be a noninvasive alternative to surgical biopsy and histopathological analysis. Our method consists of three main steps: image registration, tumor segmentation, and classification of 1p/19q status using CNN. We included a total of 159 LGG with 3 image slices each who had biopsy-proven 1p/19q status (57 nondeleted and 102 codeleted) and preoperative postcontrast-T1 (T1C) and T2 images. We divided our data into training, validation, and test sets. The training data was balanced for equal class probability and then augmented with iterations of random translational shift, rotation, and horizontal and vertical flips to increase the size of the training set. We shuffled and augmented the training data to counter overfitting in each epoch. Finally, we evaluated several configurations of a multi-scale CNN architecture until training and validation accuracies became consistent. The results of the best performing configuration on the unseen test set were 93.3% (sensitivity), 82.22% (specificity), and 87.7% (accuracy). Multi-scale CNN with their self-learning capability provides promising results for predicting 1p/19q status noninvasively based on T1C and T2 images. Predicting 1p/19q status noninvasively from MR images would allow selecting effective treatment strategies for LGG patients without the need for surgical biopsy.

*Keywords*— Low grade gliomas, 1p/19q codeletion, therapy response, convolutional neural networks

SPRINGER NATURE

Change of authorship request form

Please read the important information on page 4 before you begin

This form should be used by authors to request any change in authorship. Please fully complete all sections. Use black ink and block capitals and provide each author’s full name with the given name first followed by the family name.

Section 1 Please provide the current title of manuscript

Manuscript ID no.JDIM-D-17-00030R1

Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence

Section 2 Please provide the current authorship, in the order shown on your manuscript.

	First name(s)	Family name	ORCID or SCOPUS id, if available
1 <sup>st</sup> author	Zeynettin	Akkus	
2 <sup>nd</sup> author	Jiri	Sedlar	
3 <sup>rd</sup> author	Issa	Ali	
4 <sup>th</sup> author	Jay	Agrawal	
5 <sup>th</sup> author	Ian	Parney	
6 <sup>th</sup> author	Caterina	Giannini	
7 <sup>th</sup> author	Bradley	Erickson	

Please use an additional sheet if there are more than 7 authors.

Section 3: Please provide a justification for change. Please use this section to explain your reasons for changing the authorship of your manuscript. Please refer to the journal policy pages for more information about authorship. Please explain why omitted authors were not originally included on the submitted manuscript.

The title page was submitted with correct order, but original entry in the system did not match the title page and was incorrect. Since all authors ONLY saw the title page, not the entry into the system, they were not aware of the error, but did agree with the title page, and therefore agree with the new order in the system.



**Section 4 Proposed new authorship. Please provide your new authorship list in the order you would like it to appear on the manuscript.**

	First name(s)	Family name (this name will appear in full on the final publication and will be searchable in various abstract and indexing databases)
1 <sup>st</sup> author	Zeynettin	Akkus
2 <sup>nd</sup> author	Issa	Ali
3 <sup>rd</sup> author	Jiri	Sedlar
4 <sup>th</sup> author	Jay	Agrawal
5 <sup>th</sup> author	Ian	Parney
6 <sup>th</sup> author	Caterina	Giannini
7 <sup>th</sup> author	Bradley	Erickson

Please use an additional sheet if there are more than 7 authors.

**Section 5 Author contribution, Acknowledgement and Disclosures. Please use this section to provide revised Author Contribution, Acknowledgement and/or Disclosures of your manuscript, ensuring you state what contribution any new authors made and, if appropriate acknowledge any contributors who have been removed as authors. Please ensure these are updated in your manuscript.**

**New Disclosures (potential conflicts of interest, funding, acknowledgements):**

**New Author Contributions statement:**

**New Acknowledgement Section:**

State 'Not applicable' if there are no new authors.

Section 6 Declaration of agreement. *All* authors, unchanged, new and removed *must* sign this declaration.

*\* please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining as an author*

	First name	Family name		Signature	Affiliated institute	Date
1 <sup>st</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
2 <sup>nd</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
3 <sup>rd</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
4 <sup>th</sup> authors			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
5 <sup>th</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
6 <sup>th</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			
7 <sup>th</sup> author			I agree to the proposed new authorship shown in section 4 / <b>and the addition/removal*of my name to the authorship list.</b>			

Please use an additional sheet if there are more than 7 authors. *\* please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining.*

## Important information. Please read.

- Please return this form, fully completed, to the editorial office. We will consider the information you have provided to decide whether to approve the proposed change in authorship. We may choose to contact your institution for more information or undertake a further investigation, if appropriate, before making a final decision.
- Please note, we cannot investigate or mediate any authorship disputes. If you are unable to obtain agreement from all authors (including those who you wish to be removed) you must refer the matter to your institution(s) for investigation. Please inform us if you need to do this.
- If you are not able to return a fully completed form within **30 days** of the date that it was sent to the author requesting the change, we may have to reject your manuscript. We cannot publish manuscripts where authorship has not been agreed by all authors (including those who have been removed).
- Incomplete forms will be rejected.